CA2101775C - Methode pour abaisser l'hyperglycemie chez l'homme - Google Patents

Methode pour abaisser l'hyperglycemie chez l'homme

Info

Publication number
CA2101775C
CA2101775C CA002101775A CA2101775A CA2101775C CA 2101775 C CA2101775 C CA 2101775C CA 002101775 A CA002101775 A CA 002101775A CA 2101775 A CA2101775 A CA 2101775A CA 2101775 C CA2101775 C CA 2101775C
Authority
CA
Canada
Prior art keywords
inositol
chiro
blood sugar
elevated blood
levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002101775A
Other languages
English (en)
Other versions
CA2101775A1 (fr
Inventor
Joseph Larner
Alison Kennington
Laura C. Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Virginia Patent Foundation
Original Assignee
University of Virginia Patent Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Virginia Patent Foundation filed Critical University of Virginia Patent Foundation
Publication of CA2101775A1 publication Critical patent/CA2101775A1/fr
Application granted granted Critical
Publication of CA2101775C publication Critical patent/CA2101775C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Méthode de traitement d'un ensemble de maladies associées à des taux de glycémie élevés, prévoyant l'administration de suppléments alimentaires de chiro-inositol. Le chiro-inositol est un élément essentiel à la synthèse d'un médiateur dépendant de l'insuline qui est apparemment responsable de l'activation de la pyruvate-déshydrogénase-phosphatase. Les affections couramment associées à la résistance à l'insuline, comme l'hypertension, l'acidose lactique, l'obésité, les coronaropathies, etc. sont traitées par l'administration d'une quantité de chiro-inositol suffisante pour répondre aux besoins métaboliques.
CA002101775A 1991-01-23 1991-09-04 Methode pour abaisser l'hyperglycemie chez l'homme Expired - Fee Related CA2101775C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64463991A 1991-01-23 1991-01-23
US644,639 1991-01-23

Publications (2)

Publication Number Publication Date
CA2101775A1 CA2101775A1 (fr) 1992-07-24
CA2101775C true CA2101775C (fr) 1998-09-29

Family

ID=24585768

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002101775A Expired - Fee Related CA2101775C (fr) 1991-01-23 1991-09-04 Methode pour abaisser l'hyperglycemie chez l'homme

Country Status (5)

Country Link
EP (1) EP0568545A4 (fr)
JP (1) JPH06504278A (fr)
AU (1) AU662720B2 (fr)
CA (1) CA2101775C (fr)
WO (1) WO1992012706A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550166A (en) * 1995-03-17 1996-08-27 Ostlund; Richard E. Pinitol and derivatives thereof for the treatment of metabolic disorders
US20010039297A1 (en) * 1998-05-19 2001-11-08 Insmed Pharmaceuticals, Inc. Compositions and method for improving insulin sensivity and glucose metabolism in individuals with impaired fasting glucose or impaired glucose tolerance
CA2374269C (fr) 1999-05-20 2007-04-24 Humanetics Corporation Stimulation du transport de glucose dans un tissu animal par administration du pinitol
JP2003530111A (ja) 2000-04-07 2003-10-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング ヒトピルビン酸デヒドロゲナーゼホスファターゼ
JP4623996B2 (ja) * 2004-04-21 2011-02-02 株式会社スリービー たもぎ茸抽出物を有効成分とする血圧降下剤
WO2013016741A1 (fr) * 2011-07-22 2013-01-31 Smith Conrad Anton Complément alimentaire utilisable dans le cadre d'un programme d'amaigrissement

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801597A (en) * 1985-06-11 1989-01-31 University Of Florida Certain inositol-nicotinate ester derivatives and polyionic complexes therefore useful for treating diabetes meuitus, hyperlipidemia and lactic acidosis
EP0465508B1 (fr) * 1989-03-08 2000-05-31 The University Of Virginia Patent Foundation Preparation pharmaceutique pour diabetiques resistant a l'insuline
JPH04138126A (ja) * 1990-09-29 1992-05-12 Tookai:Kk 靴拭いマット

Also Published As

Publication number Publication date
EP0568545A1 (fr) 1993-11-10
AU662720B2 (en) 1995-09-14
WO1992012706A1 (fr) 1992-08-06
EP0568545A4 (en) 1993-11-24
AU9056691A (en) 1992-08-27
JPH06504278A (ja) 1994-05-19
CA2101775A1 (fr) 1992-07-24

Similar Documents

Publication Publication Date Title
US5428066A (en) Method of reducing elevated blood sugar in humans
CA2047686C (fr) Supplement alimentaire pour les diabetiques insulinoresistants
AU689381B2 (en) Pinitol and derivatives thereof for the treatment of metabolic disorders
US4603142A (en) Cholesterol lowering method of use
US5023248A (en) Method of treating diabetes with inositol triphosphate
AU2009200897B2 (en) Oils enriched with diacylglycerols and phytosterol ester for use in the reduction of cholesterol and triglycerides
EP1800674A1 (fr) Agent pour la prévention du syndrome métabolique
CA2101775C (fr) Methode pour abaisser l'hyperglycemie chez l'homme
Mortensen et al. Lactulose detoxifies in vitro short-chain fatty acid production in colonic contents induced by blood: implications for hepatic coma
US20200206157A1 (en) Composition for use in the prevention and treatment of pathologies of the cardiovascular apparatus
Jones et al. Coenzyme Q-10: efficacy, safety, and use
Bank et al. Galactose feeding causes glomerular hyperperfusion: prevention by aldose reductase inhibition
US7834058B2 (en) Method of using catalpic acid to treat hyperinsulinemia
ALFIN-SLATER et al. Vitamin E and lipid metabolism
Wostmann et al. The cholesterol-lowering effect of commercial diet fed to germfree and conventional rats
Winston et al. Effects of chronic ethanol ingestion on liver glycogen phosphorylase in male and female rats
JPS6260369B2 (fr)
Nordmann et al. Vitamin E disturbances during alcohol intoxication
Atef et al. Evaluation of the antioxidant effects of resveratrol against hyperglycemia-induced oxidative stress in type 2 diabetic rat model
JPH0776522A (ja) 血糖上昇抑制剤および脂質代謝改善剤
KR101751533B1 (ko) 포스파티딜콜린 및 바이페닐-디메틸-디카르복실레이트를 포함하는 간 질환 예방 또는 치료용 조성물
FR2805164A1 (fr) Medicaments contre l'atherosclerose a base de composes derives de chromone
JP2008195719A (ja) 血糖値上昇抑制剤
JP2001206842A (ja) 血中コレステロール低下作用剤
BE629983A (fr)

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed